Tarsus Pharmaceuticals Raises $60 Million in Series B FinancingHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Tarsus Pharmaceuticals Raises $60 Million in Series B FinancingPR NewswireJanuary 8, 2020ReblogShareTweetShareCapital to enable Phase 2b/3 trial for lead product TP-03 in Demodex blepharitis and additional clinical pipeline developmentIRVINE, Calif., Jan. 8, 2020 /PRNewswire/ -- Tarsus Pharmaceuticals, a clinical-stage biopharmaceutical company, today announced the completion of $60 million in Series B financing.  The financing was led by Vivo Capital and included Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners, and Horowitz Group.Tarsus Pharmaceuticals LogoMoreTarsus will use the funds to initiate a Phase 2b/3 trial in the U.S. of their lead product TP-03 for Demodex blepharitis and fuel Phase 1 and 2 development of other clinical programs.  An estimated 20 million Americans suffer from blepharitis, and approximately 45% of them have clinical signs of Demodex.  TP-03 is a topical ophthalmic that targets an underlying cause of blepharitis and has the potential to be the first-ever drug treatment for this condition.  The company's product pipeline includes additional indications in eye care and other areas of high unmet clinical need. Chen Yu, MD, MBA, Managing Partner at Vivo Capital said, "We're excited to support this innovative company that is developing the first drug for Demodex blepharitis and building a pipeline of products to address other large market opportunities."Michael Ackermann, PhD, Tarsus Chairman, commented, "We founded Tarsus with the mission of bringing to market the first drug for Demodex blepharitis, an important unmet need and one of the largest diseases in anterior segment medicine."Bobby Azamian, MD, PhD, Tarsus CEO, added, "We are grateful for support from a leading syndicate of healthcare investors.  This financing will allow Tarsus to grow, conduct a first registration study in Demodex blepharitis, and broaden our mission to deliver innovative therapies in eye care and beyond by advancing our clinical pipeline in 2020."About Tarsus PharmaceuticalsTarsus is a privately held, clinical-stage biopharmaceutical company headquartered in Irvine, California.  Tarsus was founded in 2017 to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care.  For more information, please visit tarsusrx.com.CisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/tarsus-pharmaceuticals-raises-60-million-in-series-b-financing-300983254.htmlSOURCE Tarsus PharmaceuticalsReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextDicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue EstimatesZacksSyros Pharmaceuticals, Inc. (SYRS) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacksEarnings Preview: AcelRx Pharmaceuticals (ACRX) Q4 Earnings Expected to DeclineZacksParatek Pharmaceuticals, Inc. Just Reported Yearly Earnings And Analysts Are Lifting Their EstimatesSimply Wall St.ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Lag EstimatesZacksBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoIs Link Administration Holdings Limited (ASX:LNK) Trading At A 50% Discount?Simply Wall St.Most face masks won’t protect you from the coronavirusYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video